Top Markets
#1 DeFiChain DeFiChain +2,516.54%
#2 Akedo Akedo +207.46%
#3 ONFA ONFA +54.25%
#4 Metaplex Metaplex +23.40%
#5 Osaka Protocol Osaka Protocol +21.54%
#6 Wrapped Krown Wrapped Krown +20.00%
#7 Talus Network Talus Network +19.98%
#8 DODO DODO +17.78%
#9 Black Phoenix Black Phoenix +15.09%
#10 Magma Finance Magma Finance +14.74%
Coin of the day
DeFiChain DeFiChain
Settings
Language
ENGLISH
Currency
USD
Theme
Valbiotis SA Valbiotis SA

Valbiotis SA

ALVAL
Rank in Stocks #16324
Valbiotis SA engages in the research and development of health nutrition... Valbiotis SA engages in the research and development of health nutrition products to prevent and combat metabolic and cardiovascular diseases. The company develops TOTUM-63 that is in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, which is in Phase II clinical trials to treat hypercholesterolemia; and TOTUM-854 that is in Phase II/III clinical trials for arterial hypertension. It also develops TOTUM-448 for the treatment of patient with non-alcoholic fatty liver disease. It has a strategic partnership with Nestlé Health Science. Valbiotis SA was incorporated in 2014 and is headquartered in Périgny, France.
Share Price
$0.94180721
Market Cap
$22.26M
Change (1 day)
0.38%
Change (1 year)
-14.35%
Country
FR
Trade Valbiotis SA (ALVAL)

Category

Healthcare
P/B ratio for Valbiotis SA (ALVAL)
P/B ratio as of July 2026 TTM: 2.69
According to Valbiotis SA latest financial reports and stock price the company's current price-to-book ratio (TTM) is 2.69. At the end of 2023 the company had a P/B ratio of 3.18.
P/B ratio history for Valbiotis SA from 2015 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
2026 (TTM) 2.69 16.05%
2024 2.32 -27.16%
2023 3.18 16.23%
2022 2.74 -37.95%
2021 4.41 -30.21%
2020 6.32 392.65%
2019 1.28 -22.00%
2018 1.64 -0.78%
2017 1.66 -98.28%
2016 96.41 6,215.43%
2015 1.53 0.00%
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 6.9942 159.78%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.251 132.17%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 2.1715 -19.35%
US
UCB SA UCB SA
UCB SA
UCB.BR
 4.065 50.98%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.3009 171.17%
NL